Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Medical Journal of National Defending Forces in Southwest China》 2016-04
Add to Favorite Get Latest Update

Clinical curative effects of infliximab combined with azathioprine on Crohn's disease

Chen Lan;Wen Feng;Yu Weizhong;Xia Lingli;Xiao Dan;Department of Gastroenterology, Sixth Hospital of Wuhan City,Affiliated Hospital of Jianghan University;Department of Gastroenterology, Hospital 161 of PLA;  
Objective To investigate the clinical curative effects of infliximab combined with azathioprine on Crohn's disease.Methods 180 patients with midrange or severe Crohn's disease were selected and randomly divided into azathioprine group,infliximab group, and combined treatment group with 60 cases in each group which received the treatment with azathioprine,infliximab, and the c ombination, respectively. Comparison was made in the remission rate of disease, the healing rate of mucous membrane, and ALB, TLB, WBC, CRP, and ESR before and after the treatment and the incidence of adverse reactions among the three groups. Results In the 6th week of the treatment, there was no significant difference in the remission rate among the three groups(P 0.05). In the 10 th, 18 th, and 26 th week of the treatment, the remission rate of the combination group significantly increased compared with those in the other two groups(P 0.05). In the 26 th week of the treatment, the healing rates of mucous membrane in the azathioprine, the infliximab group, and the combined treatment group were 16.67%(10/60), 28.33%(17/60), and 51.67%(31/60),respectively. The healing rate of the combined treatment group increased significantly compared with those in the other two groups(P 0.05). In the 26 th week of the treatment, the ALB and TLB levels of the three groups increased significantly compared with those before the treatment, while the WBC, ESR, and CRP levels decreased significantly(P 0.05). The improvements of those indexes in the combined treatment group was larger than those in the other two groups(P 0.05). There was no significant difference in the incidence of adverse reactions among the three groups(P 0.05), and no serious complications occurred. Conclusion The combination of infliximab and azathioprine can significantly increase the remission rate and healing rate of mucous membrane in patients with midrange or severe Crohn's disease. At the same time, it has good safety and is an effective method for the treatment on Crohn's disease.
【CateGory Index】: R574.62
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved